| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3120ae9cab5bb4831f0cc16288966367 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
| filingDate |
2014-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80cda6c692382ec3ce3832a93dbc2359 |
| publicationDate |
2016-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016296602-A1 |
| titleOfInvention |
Dosing Regimen |
| abstract |
The present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 U/administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335464-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10137172-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10596229-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11220554-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11167035-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11167014-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020002428-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112313755-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9603904-B2 |
| priorityDate |
2013-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |